TY - JOUR
T1 - Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms
AU - Drinane, Mary C.
AU - Yaqoob, Usman
AU - Yu, Haibin
AU - Luo, Fanghong
AU - Greuter, Thomas
AU - Arab, Juan P.
AU - Kostallari, Enis
AU - Verma, Vikas K.
AU - Maiers, Jessica
AU - de Assuncao, Thiago Milech
AU - Simons, Michael
AU - Mukhopadhyay, Debabrata
AU - Kisseleva, Tatiana
AU - Brenner, David A.
AU - Urrutia, Raul
AU - Lomberk, Gwen
AU - Gao, Yandong
AU - Ligresti, Giovanni
AU - Tschumperlin, Daniel J.
AU - Revzin, Alexander
AU - Cao, Sheng
AU - Shah, Vijay H.
N1 - Funding Information:
This work was supported in part by the NIH R01 DK59615 and R01 AA21171. HY is supported by National Natural Science Foundation of China (31400761) and Beijing Natural Science Foundation (7142079). FL is supported by National Natural Science Foundation of China (81472458) and Fujian Science and Technology Program (2017R1036-3). TG is supported by the Swiss National Science Foundation (P2ZHP3_168561).
Publisher Copyright:
© 2017 American Society for Clinical Investigation. All rights reserved.
PY - 2017/12/21
Y1 - 2017/12/21
N2 - The scaffold protein synectin plays a critical role in the trafficking and regulation of membrane receptor pathways. As platelet-derived growth factor receptor (PDGFR) is essential for hepatic stellate cell (HSC) activation and liver fibrosis, we sought to determine the role of synectin on the PDGFR pathway and development of liver fibrosis. Mice with deletion of synectin from HSC were found to be protected from liver fibrosis. mRNA sequencing revealed that knockdown of synectin in HSC demonstrated reductions in the fibrosis pathway of genes, including PDGFR-β. Chromatin IP assay of the PDGFR-β promoter upon synectin knockdown revealed a pattern of histone marks associated with decreased transcription, dependent on p300 histone acetyltransferase. Synectin knockdown was found to downregulate PDGFR-α protein levels, as well, but through an alternative mechanism: protection from autophagic degradation. Site-directed mutagenesis revealed that ubiquitination of specific PDGFR-α lysine residues was responsible for its autophagic degradation. Furthermore, functional studies showed decreased PDGF-dependent migration and proliferation of HSC after synectin knockdown. Finally, human cirrhotic livers demonstrated increased synectin protein levels. This work provides insight into differential transcriptional and posttranslational mechanisms of synectin regulation of PDGFRs, which are critical to fibrogenesis.
AB - The scaffold protein synectin plays a critical role in the trafficking and regulation of membrane receptor pathways. As platelet-derived growth factor receptor (PDGFR) is essential for hepatic stellate cell (HSC) activation and liver fibrosis, we sought to determine the role of synectin on the PDGFR pathway and development of liver fibrosis. Mice with deletion of synectin from HSC were found to be protected from liver fibrosis. mRNA sequencing revealed that knockdown of synectin in HSC demonstrated reductions in the fibrosis pathway of genes, including PDGFR-β. Chromatin IP assay of the PDGFR-β promoter upon synectin knockdown revealed a pattern of histone marks associated with decreased transcription, dependent on p300 histone acetyltransferase. Synectin knockdown was found to downregulate PDGFR-α protein levels, as well, but through an alternative mechanism: protection from autophagic degradation. Site-directed mutagenesis revealed that ubiquitination of specific PDGFR-α lysine residues was responsible for its autophagic degradation. Furthermore, functional studies showed decreased PDGF-dependent migration and proliferation of HSC after synectin knockdown. Finally, human cirrhotic livers demonstrated increased synectin protein levels. This work provides insight into differential transcriptional and posttranslational mechanisms of synectin regulation of PDGFRs, which are critical to fibrogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85050938173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050938173&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.92821
DO - 10.1172/jci.insight.92821
M3 - Article
C2 - 29263300
AN - SCOPUS:85050938173
SN - 0021-9738
VL - 2
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 24
M1 - e92821
ER -